Find API Reference Price of Relacorilant on PharmaCompass.com

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1496510-51-0, Cort125134, Cort-125134, Relacorilant [inn], Relacorilant [who-dd], Cort 125134
Molecular Formula
C27H22F4N6O3S
Molecular Weight
586.6  g/mol
InChI Key
WANIDIGFXJFFEL-SANMLTNESA-N
FDA UNII
2158753C7E

Relacorilant
Relacorilant is an orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration, relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.
1 2D Structure

Relacorilant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(4aR)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone
2.1.2 InChI
InChI=1S/C27H22F4N6O3S/c1-35-15-22(14-33-35)41(39,40)36-9-7-18-11-24-17(13-34-37(24)21-4-2-20(28)3-5-21)12-26(18,16-36)25(38)23-10-19(6-8-32-23)27(29,30)31/h2-6,8,10-11,13-15H,7,9,12,16H2,1H3/t26-/m0/s1
2.1.3 InChI Key
WANIDIGFXJFFEL-SANMLTNESA-N
2.1.4 Canonical SMILES
CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(CC3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
2.1.5 Isomeric SMILES
CN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
2.2 Other Identifiers
2.2.1 UNII
2158753C7E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. ((4ar)-1-(4-fluorophenyl)-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-1,4,5,6,7,8-hexahydro-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)methanone

2. Cort125134

3. Methanone, ((4ar)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-

2.3.2 Depositor-Supplied Synonyms

1. 1496510-51-0

2. Cort125134

3. Cort-125134

4. Relacorilant [inn]

5. Relacorilant [who-dd]

6. Cort 125134

7. Chembl4068611

8. Relacorilant (usan)

9. 2158753c7e

10. Relacorilant [usan]

11. [(4ar)-1-(4-fluorophenyl)-6-(1-methylpyrazol-4-yl)sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-(trifluoromethyl)pyridin-2-yl]methanone

12. Methanone, [(4ar)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(1-methyl-1h-pyrazol-4-yl)sulfonyl]-4ah-pyrazolo[3,4-g]isoquinolin-4a-yl][4-(trifluoromethyl)-2-pyridinyl]-

13. ((4ar)-1-(4-fluorophenyl)-6-(1-methyl-1h-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone

14. Methanone, ((4ar)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-

15. (r)-(1-(4-fluorophenyl)-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-1,4,5,6,7,8-hexahydro-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone

16. (r)-(1-(4-fluorophenyl)-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-1,4,5,6,7,8-hexahydro-4ah-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone

17. Relacorilant [usan:inn]

18. Schembl15454999

19. Dtxsid801099345

20. Unii-2158753c7e

21. Ex-a4253

22. Bdbm50265673

23. Nsc812727

24. Zinc141949519

25. Db14976

26. Nsc-812727

27. Ac-36530

28. Cort 125134cort 125134

29. Hy-109042

30. Cs-0031484

31. J3.651.009i

32. D11336

33. F78015

34. A936317

35. ((4ar)-1-(4-fluorophenyl)-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-1,4,5,6,7,8-hexahydro-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)methanone

36. (r)-(1-(4-fluorophenyl)-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1h-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone

2.4 Create Date
2014-03-10
3 Chemical and Physical Properties
Molecular Weight 586.6 g/mol
Molecular Formula C27H22F4N6O3S
XLogP32.9
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count11
Rotatable Bond Count5
Exact Mass586.14102241 g/mol
Monoisotopic Mass586.14102241 g/mol
Topological Polar Surface Area111 Ų
Heavy Atom Count41
Formal Charge0
Complexity1140
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty